STAT3 and chronic myelogenous leukemia, BCR-ABL1 positive: STAT3 can overcome sensitivity to BCR-ABL inhibition by driving proliferation, anti-apoptosis and MDR gene expression, increasing CML cell survival [15–19, 43].